Decibel Therapeutics Inc (Decibel Therapeutics) is a clinical-stage biotechnology company that discovers and develops transformative treatments to restore and improve hearing. The company product pipeline includes DB-OTO, AAV.103, AAV.104 and DB -020. Its product pipeline treats OTOF, GJB2, STRC and cisplatin-related hearing loss. Its pipeline therapeutic areas include congenital, monogenic hearing loss, hair cell regeneration and otoprotection. Decibel Therapeutics hair cell regeneration carries out vestibular hair cell regeneration and cochlear hair cell regeneration. The company has collaborates with Regeneron Pharmaceuticals Inc. Decibel is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
1325 Boylston Street, Suite 500, Boston, Massachusetts, 02215
Website
www.decibeltx.com
Telephone
1 617 3708701
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Products and Services
| Products |
|---|
| Pipeline |
| DB-OTO - OTOF - Related Hearing Loss |
| AAV.103 - GJB2 - Related Hearing Loss |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company signed an agreement to be acquired by Regeneron Pharmaceuticals, Inc. |
| 2021 | Contracts/Agreements | In November, the company and Regeneron extended their partnership to discover and develop gene therapies for hearing loss. |
| 2021 | Stock Listings/IPO | In January, the company announced to raise US$75 million in IPO of shares. |
Competitor Comparison
| Key Parameters | Decibel Therapeutics Inc | Fennec Pharmaceuticals Inc | Akouos Inc | Sensorion SA | Sound Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | United States of America |
| City | Boston | Research Triangle Park | Boston | Montpellier | Seattle |
| State/Province | Massachusetts | North Carolina | Massachusetts | Aquitaine | Washington |
| No. of Employees | 68 | 36 | 103 | 50 | - |
| Entity Type | Private | Public | Private | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Carson, M.D. | Chairman | Executive Board | 2021 | 64 |
| Laurence Reid, Ph.D. | President; Director; Chief Executive Officer | Executive Board | 2020 | 59 |
| Anna Trask | Executive Vice President; Chief People Officer | Senior Management | 2022 | 65 |
| Geoff Horwitz, Ph.D. | Head - Business Development; Vice President - Corporate Development | Senior Management | 2017 | - |
| Vassili Valayannopoulos, M.D., Ph.D. | Vice President; Head - Clinical Research and Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer